Integer (US:ITGR) ZACKSยท2024-07-25 14:21Core Insights - The article emphasizes the importance of earnings estimate revisions in predicting investor reactions and stock price performance [1] Sales Estimates - Analysts predict 'Sales- Medical Sales- Cardiac Rhythm Management & Neuromodulation' at $168.14 million, reflecting a +9.6% change from the previous year [2] - The consensus estimate for 'Sales- Total Medical Sales' is $429.74 million, indicating a +10.4% change year over year [6] - 'Sales- Medical Sales- Advanced Surgical, Orthopedics & Portable Medical' is estimated at $25.06 million, showing a -7.9% change from the prior year [5] - 'Sales- Non-Medical' is projected at $8.52 million, indicating a -22.1% change from the previous year [9] - 'Sales- Medical Sales- Cardio & Vascular' is expected to reach $236.43 million, reflecting a +13.4% change year over year [10] Earnings Estimates - The upcoming report from Integer (ITGR) is anticipated to show quarterly earnings of $1.24 per share, which is an increase of 8.8% compared to the same period last year [7] - Analysts forecast revenues of $438.15 million for Integer, representing a 9.5% increase year over year [7] Market Performance - Integer shares have experienced an +8.5% change over the past month, contrasting with a -0.3% move of the Zacks S&P 500 composite [7] - Integer holds a Zacks Rank 4 (Sell), suggesting it is expected to underperform the overall market in the near future [7] Analyst Consensus - There has been no revision in the consensus EPS estimate for the quarter over the last 30 days, indicating analysts' collective reassessment of their initial forecasts [3] - The article suggests that analyzing key metrics projected by analysts can provide a more comprehensive view of the company's performance [8]